News & Events
Dr. Susan Hayflick is "a bright spot" for local PKAN patient
"We had his diagnosis and we were getting ready to go home the next day and she came to our door,"Courtney said. "She told us, 'I bet you'll be as happy to meet me as I am to meet you.'" Mail Tribune
1st BPAN Research Meeting Worldwide
Dr. Rosalie Sears: PCAN Board Member
Standout Research by MMG Post-Doc
A poster presented by Meghan Joly, Ph.D., describing new insights on poor survival in pancreatic cancer, was judged the best of those by postdoctoral fellows at the International Symposium on Pancreatic Cancer 2016, held at the University of Glasgow, Scotland, in June. Originally published in the Knight News by Joseph Rojas.
Awards and Recognition
MMG Neurogeneticist Brian J. O'Roak, Ph.D., was one of a select group of researchers in the United States and Canada to be honored with a 2015 Alfred P. Sloan Research Fellowship. The highly sought-after award honors early-career scientists whose achievements and potential identify them as "rising stars." Click here to see more.
Dr. Susan Hayflick and Dr. Shelley Winn each received a 2016 OHSU Technology Transfer & Business Development Award this month. Dr. Hayflick was recognized for having received an industry SRA award from Clene, Inc. titled "The Effect of a Novel Drug on Mitochondrial Function and Viability". Dr. Winn received his award for "A (Precursor) Osteo-Progenitor Cell Line and Carrier Matrix Useful for Bone Regeneration".
Study led by Dr. Markus Grompe identifies at least four separate subtypes of human insulin-producing beta cells that may be important in the understanding and treatment of diabetes. Published in Nature Communications.
Dr. Martina Ralle recently published Activity of Menkes Disease Protein ATP7A is Essential for Redox Balance in Mitochondria in The Journal of Biological Chemistry.
BPAN research conducted by Dr. Susan Hayflick published in August 2015: Neurodegeneration with Brain Iron
Genetic Diversity and Pathophysiological
Recently Awarded Grants
- David Farrell- National Science Foundation Small Business Technology Transfer (STTR) grant titled, "Rapid Hemostatic Dressing for Hemorrhage Control", for his company, Gamma Therapeutics, to develop a new traumabandage.
- Cary Harding –NIH SBIR Subcontract award with Recombinetics titled "Development and Characterization of a Swine Model of Phenylketonuria"
- Cary Harding –NIH R01 Renewal award titled "Novel therapy for monoamine neurotransmitter deficiency in PKU"
- Susan Hayflick –NIH R13 & International Parkinson & Movement Disorder Society awards to support the International Scientific Conference on NBIA Disorders
- Penny Hogarth –Oregon Clinical &Translational Research Biomedical Innovation Program award titled "Fast-track CoACT: A novel approach to a rare disease management strategy"
- Paul Spellman –NIH U24 award titled "OHSU Center for Specialized Data Analysis as part of the GDAN"
- Paul Spellman –NIH U01 subcontract award with UCSF titled "Integrative approach to heterogeneity in breast cancer metastasis"
Brian J. O'Roak, PhD, received a Simons Foundation Undergraduate Summer Research Program award. The goal is to provide a rigorous summer research program for a talented and motivated undergraduate student with a strong interest in pursuing a career in autism spectrum disorder research.
Cary Harding, PhD,received a National PKU Alliance award for his project titled "CRISPR-Cas9-mediatedgene correction in a PKU mouse model." The goal of this project is to evaluate the efficacy of CRISPR-Cas9 genecorrection in the treatment of a mouse model of human phenylketonuria (PKU).
Susan J. Hayflick, MD, received a Sponsored Research Agreement award from Clene Nanomedicine, Inc.,for her project titled "The effect of CNM-Au8 on mitochondrial function and viability". The goal of this project is to test the efficacy of the company's drug on recovering mitochondrial viability.
Brian J. O'Roak, PhD, received a Multi-PI Simons Foundation award with Eric Fombonne, MD, titled "Oregon SPARK: National Autism Cohort 50k". The goal of this project is to recruit 50,000 subjects with autism in the US whowill provide saliva samples, will be invited to participate to future research projects, and will provide yearly data updates on their clinical status.
Rosalie Sears, PhD, received an OHSU/OSU Cancer Prevention and Control Initiative Research Pilot Award for her project titled "Bcl-2 functional converters for cancer prevention". The goal of this project is to test the efficacy of two BFCs in preventing primary and metastatic mammary and pancreatic tumors in pre-clinical models.
Penny Hogarth, MD, received a Michael J. Fox Foundation for Parkinson's Research Clinical Study award titled "Systemic Synuclein Sampling Study (S4)". The primary objective in this study is to characterize the distribution of alpha-synuclein pathology in multiple tissues and body fluids in individuals with PD as compared to HC and to evaluate the alpha-synuclein markers as potential surrogate markers for patient selection/enrichment that would be useful in future clinical trials.
Hiroyuki Nakai, MD, PhD, received a Sponsored Research Agreement award from Takara Bio, Inc. for his project titled "Development of novel parvovirus-based vectors". The goal of this project is to develop novel classes of parvovirus-based vectors with biological properties much more desirable than the currently available AAV vectors.
David Koeller, MD, received a NIH U01 award with the Pacific Northwest National Laboratory titled "Pacific Northwest Metabolomics Core for the Undiagnosed Diseases Network". His roles in this project will include providing clinical expertise in the interpretation of the metabolomic data generated by the scientists at PNNL.
Cary Harding, MD, received a Sponsored Research Agreement award from Cydan Development, Inc. for his project titled "Enteral phenylalanine dehydrogenase treatment in murine PKU". Dr. Harding's laboratory will conduct a series of pharmacology studies in the mouse model of phenylketonuria.
Brian J. O'Roak, PhD, received an award from the Ester A. & Joseph Klingenstein Fund, Inc., for his project titled "Genomic approaches to uncovering somatic mosaicism in neurodevelopmental disorders". The goal of this project is to perform a systematic evaluation of the role of somatic mosaicism in human development and risk for developing ASD and other neurodevelopmental disorders.